Abstract: Background. We retrospectively examined the treatment efficacy and toxicity profile of intensity-modulated radiotherapy (IMRT) plus concurrent weekly cisplatin chemotherapy in patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC).
reports confirm this finding. 2, 3, 10 The incidence of late toxicities has been reported less thoroughly. Even though randomized chemoradiation trials have not reported a striking increase in chronic complications, 3, 6, 7, 10 subsequent symptomspecific studies have detected significant rates of swallowing dysfunction, aspiration, and sensorineural hearing loss in patients treated with concurrent dual modality therapy. 11 The updated Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC) of concurrent chemoradiation in HNSCC confirms that either single-agent chemotherapy, utilizing a platin compound, or combination chemotherapy improves efficacy outcomes. 8 Cisplatin can be administered with concurrent radiation for HNSCC as monotherapy or as part of combination chemotherapy, and in a variety of dose and administration schedules. The most common schedules for cisplatin monotherapy in HNSCC include 100 mg/m 2 every 21 days for 2 or 3 cycles or weekly, at doses ranging from 30 to 80 mg/m 2 /week. [12] [13] [14] [15] Cisplatin can also be given daily at 6 mg/m 2 , 4, 16 or at 100 mg/m 2 spread over several days. 2, 10 Cisplatin dosed at 100 mg/m 2 every 21 days in combination with concurrent comprehensive head and neck radiation is associated with significant acute toxicities, including azotemia and dehydration. Due to the acute toxicities associated with cisplatin administered at 100 mg/m 2 , treatment compliance reported from past studies ranges from 74% to 85%; this translates roughly into a weekly dose intensity of administered cisplatin that approaches 24 mg/m 2 . [5] [6] [7] In addition, 2 recent investigations of the weekly cisplatin schedule at a planned dose of 40 mg/m 2 in combination with concomitant boost radiation for locally advanced HNSCC yielded actual dose intensities of 25.3 and 29 mg/m 2 /week due to toxicity. 12, 13 Between 1982 and 1987, the Head and Neck Intergroup conducted a phase III trial comparing radiation therapy alone with radiation and concurrent weekly cisplatin at 20 mg/ m 2 . Although the response rate was higher in patients receiving cisplatin, the median survival was only 13 months and was not statistically distinct between the 2 groups. As such, this concurrent weekly cisplatin chemoradiation regimen, dosed at 20 mg/m 2 , was not adopted as standard of care. 5, 17 Intensity-modulated radiotherapy (IMRT) offers the potential to deliver highly conformal dose-intense radiation to target regions, while sparing adjacent critical nonmalignant tissue. The improved shaping of high-dose distributions with IMRT potentially mitigates treatmentrelated toxicities. For example, the use of IMRT has been associated with increased preservation of parotid salivary flow, although improvements in patient-reported xerostomia have been modest. [18] [19] [20] [21] The use of IMRT in HNSCC is increasing, and early reports confirm its ability to secure excellent local and regional disease control. [22] [23] [24] [25] [26] Caution must be exercised, however, when comparing outcome data using IMRT with historic controls due to biases inherent in such comparisons, including an imbalance in the duration of follow-up. 27 We herein report a retrospective review of the University of Wisconsin experience of 57 patients with stage III or IV HNSCC treated with comprehensive IMRT to 70 Gy with concurrent cisplatin chemotherapy at a planned weekly dose of 30 mg/m 2 . Our purpose in doing so was to examine the outcome efficacy and tolerability of this regimen in the setting of IMRT, which aims to limit toxicity to normal tissues while maintaining tumor control.
MATERIALS AND METHODS
Patient and Staging Evaluation. Our series consisted of 57 consecutive patients with stage III or IV HNSCC who were treated with comprehensive IMRT and concurrent weekly cisplatin chemotherapy between November 2001 and May 2007 at the University of Wisconsin. All patients signed an institutional written consent for their clinical information to be entered in an institutional review board-approved comprehensive computerized database for research purposes. All patients also signed an institutional written consent for treatment. All patients were treated with definitive chemoradiation with curative intent; there were no cases in this report of postoperative adjuvant radiotherapy. Patients were selected for IMRT treatment according to the institutional practice pattern, including the use of IMRT in patients with unilateral neck metastases in whom it was desired to spare the contralateral parotid gland, in patients with bilateral neck disease well below the parotid glands, and in patients with superior pharyngeal disease where it was desired to spare the central nervous system and optic structures. In addition, patients had to be medically eligible for concurrent weekly cisplatin chemotherapy.
Pretreatment evaluation included a comprehensive history and physical exam, including either direct or fiber optic visualization of the oral cavity, oropharynx, nasopharynx, hypopharynx and larynx, a thorough dental evaluation with extractions as required, a high-quality CT of the head and neck with intravenous contrast, a head and neck MRI for selected patients, radiographic imaging of the chest (x-ray or CT), complete blood counts, and positron emission tomography (PET) scans for selected patients. Disease was staged according to the 1998 American Joint Committee on Cancer staging classification.
Chemotherapy. Chemotherapy was administered under the care of 2 medical oncologists (A.M.T. and J.F.C.). Patients received intravenous cisplatin dosed at 30 mg/m 2 weekly throughout the duration of their radiation. They were evaluated weekly by the nursing staff and typically seen every other week by the treating physician. Treatment included 1 liter of normal saline prehydration, followed by dexamethasone and a 5HT3 antagonist antiemetic. In addition, prochlorperazine and lorazepam antiemetics were added as needed. Cisplatin was mixed in 1 liter of normal saline and infused over 1 hour. A complete blood count and a serum creatinine were obtained with each weekly treatment. Cisplatin was administered only if the absolute neutrophil count !1500/lL and platelets !100,000/lL. The cisplatin dose was reduced to 20 mg/m 2 in the event of grade 2 nephrotoxicity, nausea, or vomiting. Cisplatin was held if the above hematologic parameters were not met, or with any grade 3 nonhematologic toxicity occurring during the preceding week.
Radiation Treatment Planning and Delivery. Radiation therapy was administered under the care of 2 radiation oncologists (P.M.H. and D.K.). All patients underwent a treatment planning CT scan with intravenous contrast. Patients were fitted with a customized thermoplastic mask to immobilize the head and neck. Patients treated with linear accelerator-based 7-field IMRT were fitted with a custom maxillofacial bite tray system embedded with optical fiducial markers to facilitate highly precise localization and delivery of radiation treatments as previously described. 28 Patients treated with helical tomotherapy IMRT underwent daily megavoltage CT treatment scans for position verification and adjustment as needed before each radiation treatment delivery.
CT-based treatment planning was performed using the Pinnacle 3 treatment planning system (Pinnacle, Philips Medical Systems, Andover, MA) for 7-field IMRT linac plans. For tomotherapy plans, all volumes were contoured in Pinnacle and then transferred into the TomoTherapy Hi Art treatment planning system (TomoTherapy, Madison, WI). All areas of gross disease, including the primary disease and all positive lymph nodes, were contoured as gross target volume (GTV). The clinical target volume (CTV), defined as areas at risk for microscopic disease outside of the GTV, was also contoured. The high-risk CTV (CTV 1 ) typically encompassed the GTV plus a margin and the regional lymphatics at highest risk for subclinical disease. In patients with unilateral nodal disease, a lowerrisk CTV (CTV 2 ) encompassed the contralateral neck lymphatics. An additional lower-risk CTV (CTV 3 ) was created for the low-neck and supraclavicular lymph nodes for patients treated with helical tomotherapy; the low-neck and supraclavicular lymph nodes were commonly treated with an anterior-posterior (AP) field for patients receiving linac-based IMRT.
Planning target volumes (PTV) were generated to account for setup error and organ motion. Normal anatomic structures, including the parotid glands, spinal cord, brainstem, optic nerves, and lens of the eye were contoured. Typical dose constraints to normal structures included: contralateral parotid 22.5 Gy to 30% volume, spinal cord max dose 35 Gy, brainstem max dose 50 Gy, lens max dose 2 Gy. Dose-volume histograms were generated and reviewed by the treating physician for each case to ensure individual optimization of constraints. IMRT treatments were delivered using either continuous optical guidance during treatment (7-field IMRT) or daily megavoltage CT scanning before treatment (helical tomotherapy) to enhance setup precision. Treatments were delivered using 6 MV photons. Linac-based IMRT was performed using a step-and-shoot technique.
Surgery. No definitive surgery, aside from diagnostic biopsy, was performed on the primary site of disease in any patient within this report. One patient underwent a modified radical neck dissection before chemoradiation as part of his diagnostic evaluation at an outside institution. Thirty patients underwent a postchemoradiation neck dissection. Surgical salvage was considered for patients who experienced local or regional disease recurrence.
Follow-up
Radiographic follow-up commonly included a CT scan within the first 6 months posttreatment, followed by annual chest x-rays. Additional imaging studies were ordered as clinically indicated. The median follow-up for all patients is 27 months.
Statistical Methods. All statistical analyses, including Kaplan-Meier curves, were performed using MedCalc v 9.3.2.0 (MedCalc Software, Belgium). Clinical data were collected retrospectively from reviews of patients' charts performed by 3 clinical research associates and reviewed by the first and second authors. These data were then entered into our computerized database for research purposes and analyzed by the first and second authors for this report. Toxicities were evaluated and scored using the NCI CTCAE version 3.0. Table 1 lists demographic and clinical characteristics of the treatment cohort.
Treatment Details and Compliance. The overall treatment compliance for patients in this study was quite good ( Table 2 ). The median radiation dose delivered to the high-risk PTV was 70.0 Gy with dose per fraction ranging from 2.0-2.2 Gy (median 2.1 Gy). The median doses to PTV 60 , PTV 54 , and PTV 50 were 60 Gy, 54 Gy, and 50 Gy, respectively. The median overall treatment time for IMRT was 45 days (range, 41-56 days). No patient required a treatment break greater than 2 consecutive days. One patient had a total of 4 days of treatment breaks, each occurring on single, nonconsecutive days due to transportation difficulties. All patients received the prescribed radiation dose.
The median number of chemotherapy cycles delivered per patient was 5.5, thereby yielding a mean dose intensity of 25.7 mg/m 2 /week (range, 5-34.3 mg/m 2 ). Of 369 planned cisplatin doses, 311 (84.2%) were delivered and 15.7% were omitted. One patient received 1 dose beyond that initially planned. Nine (3%) of the 311 delivered planned doses were administered at an adjusted dose of 20 mg/m 2 due to treatmentrelated toxicity. Thirty-three patients (57.9%) received at least 6 cisplatin cycles; only 5 patients (8.7%) received fewer than 4 cycles. Nine patients (15.8%) received a seventh dose and 1 patient received an eighth dose due to the timing and duration of their IMRT course.
Postchemoradiation neck dissections were performed in 30 patients: 27 selective neck dissections and 3 modified radical neck dissections. One patient underwent a modified radical neck dissection before chemoradiation treatment as part of his diagnostic evaluation at an outside institution. Salvage surgical resections were performed in 3 patients. One patient who had a local hypopharyngeal recurrence underwent total laryngopharyngectomy with bilateral selective neck dissection. A second patient was found to have persistent local disease involving the tongue base at the time of his planned posttreatment neck dissection; therefore, he underwent a composite resection of the tongue base, right oropharynx, and right soft palate, and a right modified radical neck dissection. Finally, a third patient with left neck recurrence underwent a revision neck dissection consisting of a modified radical neck dissection with extension to remove infraclavicular lymph nodes.
Treatment Outcome. With a median follow-up of 27 months, there have been 7 local failures, 2 of which manifested as incomplete tumor regression (persistence) after primary treatment. Two of these 7 local failures (29%) occurred in patients with nasopharyngeal primaries. Five patients experienced recurrent disease in the neck. With a median follow-up of 27 months, the Kaplan-Meier estimate, as depicted in Table 3 , shows in-field tumor control at 2 years of 89.1%, regional control in the neck of 90.6%, locoregional control of 85.5% (Figure 1) , freedom from distant metastases of 88.9%, and overall survival of 86.9% at 2 years (Figure 2) .
Toxicities. Twelve patients (21%) were hospitalized during treatment: 9 for nausea, vomiting, and dehydration; 1 for febrile neutropenia; 1 for candidal esophagitis; and 1 for a feeding-tube complication. Twenty-four patients (42%) experienced grade 2, and 29 (51%) developed grade 3 mucositis. All cases of mucositis fully resolved by 12 weeks. Two patients (4%) experienced grade 3 hyperkalemia; there were no occurrences of nephrotoxicity. Table 4 lists the acute treatment-related toxicities that occurred in at least 5% of patients. The median weight loss during treatment was 8.2 kg (range, 0.9-18.2 kg), with 24 patients (42%) losing greater than 10% of their pretreatment body weight. Chronic treatment-related toxicities are listed in Table 5 . Of the 34 patients in whom a percutaneous gastrostomy tube was placed before treatment, 7 (20%) retained the tube at 6 months posttreatment, and 1 patient (3%) had it at 12 months.
DISCUSSION
Our experience suggests that comprehensive head and neck IMRT to 70 Gy delivered with concurrent weekly cisplatin chemotherapy at 30 mg/m 2 is feasible and generally well tolerated in patients with locoregionally advanced HNSCC.
Given the substantial limitations of comparing retrospective single-institution data with prospective multi-institution phase III results, our 2-year efficacy outcomes are encouraging, compared with those from chemoradiation trials incorporating standard (non-IMRT) radiotherapy. [2] [3] [4] [5] 10 In addition, we identified lower rates of acute toxicity compared with those seen in phase III trials using non-IMRT treatment. This finding is consistent with reports of modest improvements in xerostomia and quality of life from prospective studies comparing IMRT treatment with standard radiotherapy. 18, 21 The limitations of comparing our single institution retrospective data with prospective results are significant, and include variances in toxicity evaluation and reporting, patient population, duration of followup, and treatment intensity. 27 Nonetheless, it is possible to speculate that the conformal dose distributions seen with IMRT may lower rates of acute toxicity to skin, mucosa, and salivary glands when combined with weekly cisplatin. However, expertise in head and neck IMRT target design, normal tissue dose constraints, patient immobilization, and treatment delivery are all critical elements that can influence outcome.
Comparisons of our experience with that from larger single-institution retrospective series of chemoradiation using IMRT are limited by differences in treatment populations and the variable types of chemotherapy used (although most incorporated cisplatin at 100 mg/m 2 on a 21 day schedule). [22] [23] [24] [25] [26] 29, 30 Nonetheless, our efficacy results at 2 years are comparable to these series, and our toxicity analyses suggest reduced rates of acute adverse events. For example, in a series of 41 patients undergoing IMRT with concurrent chemotherapy (usually cisplatin at 100 mg/m 2 every 21 days) for stage III and IV oropharyngeal cancer, Lee et al 23 describe rates of at least grade 3 acute toxicities (mucositis, skin reactions, hematologic, nausea, and vomiting) that exceed those in our series. Treatmentrelated xerostomia was the primary chronic toxicity consistently reported in these series, with grade 2 xerostomia ranging from 3% to 32%. 23, 29, 30 Forty-six percent of our patients experienced grade 2 xerostomia. This higher rate of xerostomia may be due to treatment, or possibly to more consistent rates of follow-up evaluations occurring in our cohort of predominantly local patients, who have high rates of adherence to follow-up. Regarding rates of other chronic treatmentrelated toxicities, low-grade laryngeal edema was observed in 26% of patients in this series, particularly in patients in whom the primary tumor resided within or directly contiguous to the larynx. For oropharyngeal patients (69% in this series), we employed conformal IMRT techniques that specifically limited dose to the larynx in an effort to minimize laryngeal edema and dysfunction. Forty percent of patients in this report manifested some degree of soft tissue thickening and low-grade fibrosis in the neck. This was seen more commonly in patients who underwent a neck dissection. However, no advanced cases of cervical fibrosis or necrosis have been observed. Two patients developed grade 3 esophageal stricture requiring endoscopic dilatation. Aside from these 2 patients, there were no additional cases of grade 3 or greater chronic toxicities identified in this series to date. However, our median follow-up is only 27 months, and these late complications can certainly emerge with longer term follow-up.
Our retrospective review of the use of IMRT and weekly cisplatin chemotherapy in locally advanced HNSCC is limited by several variables. Patient selection factors may well have contributed to favorable results in this report, given that patients had disease distributions amenable to IMRT treatment, therefore likely favoring a population with a lower percentage of bulky bilateral disease. In addition, our patients were predicted to tolerate concurrent chemotherapy. Nonetheless, we hope our findings serve to identify the need for randomized comparisons of weekly cisplatin in IMRT-based prospective trials in the treatment of HNSCC.
Any consideration of our efficacy outcomes must also take into account that 69% of patients in this report had oropharyngeal primaries. Although human papillomavirus (HPV) status was not evaluated in these patients, HPV is common in this group and is a favorable prognostic factor that may have contributed to the favorable treatment results for this group as a whole. 31 In addition, although only 6 (11%) of our 57 patients had a nasopharyngeal primary site of disease, they accounted for 2 (29%) of the local recurrences (both patients had T 4 N 2 disease). Therefore, we elected to keep these 6 patients in our efficacy analyses because they did not favorably influence the overall outcome.
In conclusion, our retrospective, single-institution review suggests that comprehensive head and neck IMRT to 70 Gy delivered with concurrent weekly cisplatin chemotherapy at 30 mg/m 2 is feasible and generally well tolerated in patients with locoregionally advanced HNSCC. It has been more than 2 decades since the Head and Neck Intergroup conducted a phase III trial comparing radiation therapy alone with radiotherapy and concurrent weekly cisplatin at 20 mg/m 2 . 17 Interval advances in supportive care, patient characteristics (more HPV-positive patients), and in radiation technologies suggest that a prospective, randomized comparison of weekly cisplatin versus every 3 week high-dose treatment, administered concurrently with IMRT, would be helpful to provide the most rigorous evaluation of this treatment regimen.
